KBB Of South Korea Prepares To Mass Produce Bone Regenerating Proteins
This article was originally published in PharmAsia News
The Korea Bone Bank in South Korea says it is preparing to mass produce bone morphogenetic proteins while moving to complete clinical trials and obtain regulatory approval by the end of this year
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.